Qi F. Dang

5 Yushan Road
Qingdao, 266003, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

First-in-human evidence of multidrug resistance reversal in solid tumors: a cohort analysis of carbon nanoparticles‑Fe(II) complex trials.

First-in-human evidence of multidrug resistance reversal in solid tumors: a cohort analysis of carbon nanoparticles‑Fe(II) complex trials.

Journal: BMC cancer
Published: March 20, 2026

TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.

TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study.

Journal: Cancer cell
Published: April 29, 2025

Targeted combination chemotherapy effective in nuclear protein in testis carcinoma of lung origin: A case report and review of the literature.

Targeted combination chemotherapy effective in nuclear protein in testis carcinoma of lung origin: A case report and review of the literature.

Journal: Medicine
Published: February 19, 2025

The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.

The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.

Journal: Nature medicine
Published: January 22, 2025

The risk of rash for cancer patients treated with PD-1/PD-L1 inhibitors: An updated systematic review and meta-analysis.

The risk of rash for cancer patients treated with PD-1/PD-L1 inhibitors: An updated systematic review and meta-analysis.

Journal: Medicine
Published: September 13, 2024

PD-L1 has a stronger effect on increasing headache risk than PD-1: a systematic review and meta-analysis.

PD-L1 has a stronger effect on increasing headache risk than PD-1: a systematic review and meta-analysis.

Journal: Cancer cell international
Published: April 03, 2024

Differences in the risk of immune-related pneumonitis between PD-1 and PD-L1 inhibitors: a meta-analysis according to the new mirror-principle and PRISMA guidelines.

Differences in the risk of immune-related pneumonitis between PD-1 and PD-L1 inhibitors: a meta-analysis according to the new mirror-principle and PRISMA guidelines.

Journal: Cancer immunology, immunotherapy : CII
Published: January 26, 2024

Prognostic value of body mass index for first-line chemoimmunotherapy combinations in advanced non-small cell lung cancer in Chinese population.

Prognostic value of body mass index for first-line chemoimmunotherapy combinations in advanced non-small cell lung cancer in Chinese population.

Journal: Heliyon
Published: January 14, 2024

Efficacy of first-line treatment options beyond RET-TKIs in advanced RET-rearranged non-small cell lung cancer: A multi-center real-world study.

Efficacy of first-line treatment options beyond RET-TKIs in advanced RET-rearranged non-small cell lung cancer: A multi-center real-world study.

Journal: Cancer medicine
Published: September 27, 2023

Nonfunctional ectopic adrenocortical carcinoma in the lung: A case report and literature review.

Nonfunctional ectopic adrenocortical carcinoma in the lung: A case report and literature review.

Journal: Frontiers in oncology
Published: November 17, 2022

Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis.

Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis.

Journal: Medicine
Published: September 10, 2022

Polyethyleneimine-assisted co-deposition of polydopamine coating with enhanced stability and efficient secondary modification.

Polyethyleneimine-assisted co-deposition of polydopamine coating with enhanced stability and efficient secondary modification.

Journal: RSC advances
Published: August 16, 2022
Showing 1-12 of 29

Last Updated: 09/26/2026